Making an in vitro diagnostic assay has never been easy. Now with the global lab and supply chain and disruptions caused by the COVID pandemic, the development and manufacture of IVDs faces further challenges.
Fortunately, the successful commercialization of your assay in these turbulent times and beyond can benefit from some important, often overlooked considerations in design and planning.
Attend the virtual, two-day IVD conference where international technical experts and scientists will address key aspects of IVD immunoassay (CLIA, immunoturbidimetry, qualitative and quantitative lateral flow, etc.) development and performance, including:
Join us to learn about current and future IVD technologies and market trends, both now, and post-COVID from industry leaders, while taking advantage of networking opportunities and a supplier exhibition. We look forward to staying connected with you virtually!
The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
Matt is currently the product training manager of Diagnostics Solutions for MilliporeSigma. His primary responsibility is driving technology and product education to MilliporeSigma’s global customer base. Prior to this, he held a post-doctoral fellowship at Washington University in St Louis, MO, and earned a Ph.D. in Cell and Molecular Biology from the University of Hawaii at Manoa where his research focused on embryonic development and stem cell biology.
R&D and R&A director, co-founder of MagIA diagnostics
2014 - 2017
PhD student in Biotechnology
G2Elab - IAB (Grenoble)
Fast innovative immunoassays exploiting superparamagnetic nanoparticles and micro-magnets
Institut Pasteur de Madagascar
Development of molecular biologic tools for detection, identification and genotype of opportunistic parasites (Microsporidia) in diarrheic children in Madagascar
LMGP - G2Elab (Grenoble)
Development of a Biologic Magnetic Micro-Electro- Mechanical System involved in the immunodiagnostic of HCV antigen
Production and purification of proteins BMP9 and BMP10 on HEK 293
Patrick DUCOROY received his PhD from Dijon, Bourgogne University (2002). He was a research assistant and head of Proteomics Studies for the Department of Exploratory Biology of Laboratoires FOURNIER, Solvay Pharmaceuticals Company, Dijon (2002-2004). Patrick DUCOROY has managed the biotechnological platform “Clinical & Innovation Proteomic Platform (CLIPP)” from Bourgogne/Franche-Comté University (2005-2015). Patrick DUCOROY’s research was focused on the combining knowledge and know-how in the fields of proteomics, mass spectrometry, chemistry, nano engineering, biostatistics and bioinformatics to respond to the problematics of biologists and to develop new approaches and/or original tools for the analysis of proteomics.
In 2016, Patrick DUCOROY founded BIOMANEO company with Valérie GEOFFROY. He pursues his research and development on the set up of methodologies of high throughput screening including Proteomics analytical tools combined with IT solutions adapted to help the interpretation of results. Patrick DUCOROY’s research is focused on the setup of plug and play analytical solutions since the samples until the interpretation of results, including technologies such as MALDI, LC-MS/MS, RAMAN….Research Patrick DUCOROY’s is focused on the hemoglobinopathies and initiated the adaptation of methods (nano biosensors, Mass spectrometry and bioinformatics tools) for the screening of other pathologies such as cystic fibrosis, cancer (Liver, Bladder), neurodegenerative disease (Alzheimer), infection (COVID19)…
Dr Charlie Huang has more than 20 years of experience in the multi-discipline environment. He is a full spectrum industrial executive with experiences ranging from concept generation, upstream research, product design, development, manufacturing to commercialisation.
He has demonstrated scientific expertise in the fields of life sciences, in vitro diagnostics, biotechnology and nanotechnology. He also has significant commercial expertise in business development, commercial strategy, project & team management, technology analysis & transfer, licensing and intellectual proprieties.
Prior to joining Anteo, he has held senior management roles in several public listed healthcare and IVD companies including Panbio Ltd, Alere, Cellestis Ltd and QIAGEN. He is working with the Anteo team to develop strategies, patents, products and services for industrial and life science applications and commercialisation.
He holds a BSc in Life Science and an MSc in Molecular Engineering from NCHU. He obtained his PhD in Biochemistry and Molecular Biology from the University of Queensland in 2000. He has published scientific papers with strong impact factors and is co-inventor of many granted patents in the fields of novel diagnostics, medical devices, metal complex applications and energy.
Virginia obtained a Science Bachelor’s degree in Biochemistry and a PhD in Science from Zaragoza University in Spain.
She joined OPERON S.A. as Project Manager at the Lateral Flow (LF) R&D Department in 2010. She was in charge of the design and development of rapid tests.
Since 2015, she works as LF Product Specialist at the Sales & Marketing Department designing product specifications, providing technical support and managing contract manufacturing accounts.
Dr. Anabel Lermo is a Research Scientist with demonstrated experience in the field of In-Vitro Diagnostic (IVD), skilled in the design of complex platforms for immunoassay sensing.
She holds a PhD in Chemistry (Honoured) from the UAB of Barcelona. Her thesis was focused on the design of biomolecular approaches in electrochemical biosensing devices for alimentary field. She worked as a postdoctoral fellow at Analytical Chemistry Division UAB as a leading researcher of investigation projects for immunoassay development applied to biosensor design in the alimentary and clinical fields. Then, she joined Biokit (a company of the Werfen group) for 7 years, developing chemiluminescent immunoassays for automated platforms in the field of infectious diseases. Her activities were mainly focused on the optimization of key component formulation and analyser assay parameters, transferring the reagent to production, generating all the documentation required for verification, validation and registration of the product in various regulatory agencies (CE, Shonin and CFDA).
She currently works at Pragmatic Diagnostics developing new assays where immunometric technologies are integrated with appropriate analytical platforms in a streamlined and efficient manner for IVD industry.
Founder of SEPMAG, Lluis holds a Ph.D. in Magnetic Materials from the UAB. He has conducted research in German and Spanish academic institutions. Having worked in companies in Ireland, the USA, and Spain, he cumulates more than 20 years of experience, applying magnetic materials and sensors to industrial products and processes. He has filed several international patents on the field and co-authored more than 30 scientific papers, most of them related to the movement of magnetic particles.
Vicepresident of Spanish Biotech Companies Association (ASEBIO)
Chief Executive Officer | ARRAYS FOR CELL NANODEVICESSL | MADRID
September 2019 – Today
General management of the company
Scaleup of disruptive technology from CSIC licensed by A4Cell
Create company, brand, product and applications from the initial project
Sectors: High Content Screening market and cell therapy
Business Development Manager | NANOIMMUNOTECH SL | MADRID
December 2016 – August 2019
Leadership and management of the sales and marketing team
Starting of the international marketing strategy for HEATSENS Technology
Search for partners who want to launch Heatsens in their developments
Sectors: IVD Diagnostic, research, food safety and animal health
Brand Manager | BIOMEDAL, SL | MADRID
December 2008 – December 2016
Leadership and management of the sales and marketing team
Management of the food safety business
Designing of the strategic business for gliadin detection test
Searching of the network distributors around the world.
Launching of the first test to detect toxic peptide in urine samples for coeliac patients.
Spanish product manager of Bioneer Inc.
Product Manager | Bonsai Technologies Group, SL | MADRID
July 2006 – November 2008
Product manager for Spanish and Portuguese market of three big international suppliers (BIOHIT, BIORON and AXYGEN)
Product Manager | INGENASA, SA | MADRID
September 2001- June 2006
Manager of the food safety product line as a strategic business
Leadership of the sales team and dealers.
Since November 2018 Chief Scientific Officer (CSO)
- responsible for the development of IVD products (diagnostic tests) and non-IVD products (SERION Immunologics)
Since November 2013 Director of SERION Immunologics
- responsible for the newly formed business unit SERION Immunologics focussing on the development and sales of critical raw materials like antigens, antibodies, beads and reagents for infectious serology
2012 - 2018 Senior manager antigen production and research & development
2008 - 2011 Department head antigen production
2007 - 2008 Group leader at Siegfried-Biologics GmbH, Berlin, Germany
2006 - 2007 Research Scientist at responsif GmbH, Erlangen, Germany
2005 - 2006 PostDoc at the RWTH, Aachen, Germany
2005 PhD at the RWTH Aachen, Germany, in the field of chemo-enzymatic synthesis of novel erythromycin antibiotics
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events